

# MariÃ«tte E Botes

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10892884/publications.pdf>

Version: 2024-02-01

13  
papers

1,150  
citations

840119

11  
h-index

1125271

13  
g-index

13  
all docs

13  
docs citations

13  
times ranked

1539  
citing authors

#	ARTICLE	IF	CITATIONS
1	HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 750-759.	4.6	258
2	Unnecessary Antiretroviral Treatment Switches and Accumulation of HIV Resistance Mutations; Two Arguments for Viral Load Monitoring in Africa. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 58, 23-31.	0.9	176
3	Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 307-317.	4.6	162
4	Patterns of HIV-1 Drug Resistance After First-Line Antiretroviral Therapy (ART) Failure in 6 Sub-Saharan African Countries: Implications for Second-Line ART Strategies. <i>Clinical Infectious Diseases</i> , 2012, 54, 1660-1669.	2.9	144
5	Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2918-2927.	1.3	75
6	Second-Line Antiretroviral Treatment Successfully Resuppresses Drug-Resistant HIV-1 After First-Line Failure: Prospective Cohort in Sub-Saharan Africa. <i>Journal of Infectious Diseases</i> , 2012, 205, 1739-1744.	1.9	61
7	Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study. <i>Lancet HIV</i> , the, 2018, 5, e638-e646.	2.1	56
8	Cohort Profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) Monitoring Studies to Evaluate Resistanceâ€”HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. <i>International Journal of Epidemiology</i> , 2012, 41, 43-54.	0.9	53
9	HIVâ€”HBV Coinfection in Southern Africa and the Effect of Lamivudine- Versus Tenofovir-Containing cART on HBV Outcomes. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 64, 174-182.	0.9	53
10	Pretreatment HIV Drug Resistance Increases Regimen Switches in Sub-Saharan Africa. <i>Clinical Infectious Diseases</i> , 2015, 61, civ656.	2.9	51
11	Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa. <i>Journal of Infectious Diseases</i> , 2016, 214, 873-883.	1.9	41
12	Phase I trial with oral oxihumate in HIV-infected patients. <i>Drug Development Research</i> , 2002, 57, 34-39.	1.4	10
13	Building Capacity for the Assessment of HIV Drug Resistance: Experiences From the PharmAccess African Studies to Evaluate Resistance Network. <i>Clinical Infectious Diseases</i> , 2012, 54, S261-S265.	2.9	10